COSMETIC OR CLEANING COMPOSITION AND CONSUMER PRODUCT

专利摘要:
all-natural composition and consumer product. the present invention provides a formulation comprising various natural extracts for a variety of human applications.
公开号:BR112013014236B1
申请号:R112013014236-7
申请日:2011-12-08
公开日:2021-03-30
发明作者:Tova Silberstein
申请人:Y&B Mother's Choice Ltd；
IPC主号:

专利说明:

FIELD OF THE INVENTION
This invention relates to formulations that comprise saponins and their uses in a variety of cosmetic, therapeutic and preservative applications. BACKGROUND OF THE INVENTION
As is known in the art, saponins are compounds constructed of a chemical portion of steroid or triterpene (aglycone or sapogenin) and one or two chemical portions of glycoside (monodesmosides or bidesmosides, respectively). The main carbon chain of aglycone may be saturated or unsaturated and / or may comprise a heteroatom such as nitrogen. The chemical portion of glycoside contains sugars such as galactose, glucose, glucuronic acid, methylpentose, rhamnose and xylose.
The saponin family is known to have a wide range of biological activities such as cytotoxic, anti-herbivorous and / or antimicrobial activities and its role in nature is likely to be the defense against pathogens, pests and predators. And plants, saponins appear to act as preformed antimicrobial barriers to pathogen attack, but they can also function as suppressive defense responses induced after hydrolysis [1].
Public concern about the safety of synthetic preservatives used in cosmetics and food, especially in relation to their accumulation and subsequent effect on health, has led health authorities to reduce applied concentrations or even to ban synthetic preservatives. Alternatives such as plant antimicrobial substances are the focus of much research, however, due to their low potency, narrow range and high prices, they are rarely used to replace synthetic preservatives.
The state of the art includes attempts to use naturally occurring compounds in cosmetic compositions. For example: Document No. US 2011/0020302 [2] discloses a cosmetic composition that comprises naturally occurring ingredients that have 0.1 to 20 w / w of Lonicera species. WO 2000/072861 [3] discloses a method of extracting bioactive substances such as saponins from plants through supercritical fluid extractions. WO No. 1998/048768 [4] discloses a cosmetic composition comprising extracts of Camellia and Lonicera species as possible additives. US No. 2006/0018867 [5] discloses a cosmetic composition comprising epsilon polylysine compounds containing polyorganosiloxane and an antimicrobial agent. Lonicera japonica extract is mentioned among a very long list as an anti-inflammatory agent, an astringent and as a tyrosinase inhibitor. Saponins are mentioned as antimicrobial agents and as a pigmentation inhibitor. The order also teaches the optional addition of a saponin as a humectant and / or a natural surfactant. WO 2009153800 [6] teaches saponin extractions from Sapindus trifoliatus.
REFERENCES [1] "The saponins - polar isoprenoids with important and diverse biological activities" A. Osbourn, et al., Nat. Prod. Rep., 2011, 28, 1261; [2] U.S. Order No. 2011/0020302; [3] WO 2000/072861; [4] WO 1998/048768; [5] Order No. U.S. 2006/0018867; [6] WO 2009153800; [7] U.S. Patent 4,247,569; [8] U.S. Patent 2,996,540; [9] Order No. U.S. 2010/183528. SUMMARY OF THE INVENTION
The inventors of the invention found, surprisingly, that compositions of at least one saponin material and an extract of at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or any mixture of extracts from them exhibit biological activity, for example, antimicrobial activity, which is superior to the activity shown for each component individually and which is at least comparable and even superior to the chemical alternatives known for a particular use.
In its first aspect, the invention provides a composition comprising at least one saponin material and an extract from at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture thereof.
As used herein, the "saponin material" is at least one saponin compound obtained naturally, as known in the art. When isolated from a natural source, at least one saponin can be used in its substantially pure form (namely at least 85%, 87%, 92%, 95%, or 98% purity), or it can be used as an extract containing saponin isolated by a method known in the art or by a method of the invention, as disclosed herein.
In accordance with the present invention, the extract containing saponin (referred to herein for brevity as "saponin extract") contains at least between 0.2% and 95% by weight of saponins, out of the total weight the dry content of the extract. In some embodiments, the extract used in accordance with the present invention comprises between 0.2% and 99%, by weight, of saponins out of the total weight of the dry content of the extract.
In some embodiments, the extract used in accordance with the present invention comprises between 10% and 80%, by weight, of saponins out of the total weight of the dry content of the extract. In other embodiments, the extract used in accordance with the present invention comprises between 10% and 60%, by weight, of saponins among the total weight of the dry content of the extract. In additional embodiments, the extract used in accordance with the present invention comprises between 10% and 50%, by weight, of saponins among the total weight of the dry content of the extract. In additional embodiments, the extract used in accordance with the present invention comprises between 10% and 40%, by weight, of saponins among the total weight of the dry content of the extract. In still further embodiments, the extract used in accordance with the present invention comprises between 10% and 30%, by weight, of saponins among the total weight of the dry content of the extract.
In some embodiments, the extract used in accordance with the present invention comprises between 10% and 20%, by weight, of saponins out of the total weight of the dry content of the extract.
In some embodiments, the extract used in accordance with the present invention comprises between 0.2% and 10%, by weight, of saponins out of the total weight of the dry content of the extract.
The saponin-containing extract can be obtained from any natural source known to comprise saponins. Such a natural source can be a plant source, some of which are detailed above, and also from a non-plant source such as animal sources and marine organisms, such as asteroids and holoturias. In some embodiments of the invention, saponins are extracted from a plant source, naturally grown or genetically modified to have a high saponin content.
In some embodiments of the invention, the saponin material is obtained by extracting a vegetable source using water, alcohol or a water / alcohol solution. In some embodiments, the alcohol is ethanol or methanol.
In some modalities, extraction is achieved using a water / alcohol solution. In some embodiments, the water / alcohol solution has a water: alcohol ratio between 80:20 and 20:80. In additional modalities, the water / alcohol solution has a water: alcohol ratio between 60:40 and 40:60. In additional modalities, the water / alcohol solution is 80:20 water / alcohol, 60:40 water / alcohol, 50:50 water / alcohol, 40:60 water / alcohol ratio or 20/20 water / alcohol : 80.
The extraction time can vary without limitation from 1 to 8 hours, at or above room temperature (20 ° C to 30 ° C), for example, above 30 ° C, 40 ° C, 50 ° C or 60 ° C . In some embodiments, extraction is carried out at a temperature between 30 ° C and 70 ° C.
In some embodiments, the saponin material is obtained from a plant source. The vegetable source can be selected from shikakai, soybeans, beans, peas (Pisum sativum), alfalfa, tea, spinach, sugar beet, quinoa, licorice, sunflower, horse chestnut, ginseng, oats, capsicum peppers, eggplant , tomato seeds, allium, asparagus, yam, fenugreek, yucca and ginseng, alfalfa, mung bean, Bupleurum falcatum, Camellia oleifera, Camellia Gypsophila, quinqufolius, Panax japonicas, Quillaja saponaria, Sapindus delavayi, Sapindus mukorossi, Sapindus mukorossi, Sapindus mukorossi, Sapindus mukorossi, Sapindus mukorossi, Sapindus mukorossi , Sapindus saponaria, Sapindus trifoliatus, Saponaria officinalis, Styrax japonica, and Yucca schidigera or any mixture thereof. Any part of the plant can be used to extract saponin material, including leaves, stems, roots, bulbs, flower and fruit (including the skin, flesh and seed of the fruit).
In some embodiments, the saponin material is an extract from Camellia sinensis, Camellia oleifera, Saponaria officinalis or Sapindus mukorossi or a mixture thereof.
In other embodiments, the saponin material is an extract of Camellia oleifera, or Sapindus mukorossi or a mixture thereof.
Saponin material obtained from a plant source, for example, Camellia oleifera and / or Sapindus mukorossi, can be extracted as disclosed below in this document. In some modalities, the extraction process comprises: treating the plant source in a water / alcohol solution under conditions that allow the extraction of the saponin material into the solution. The saponin-containing material thus extracted can subsequently be purified by any means known in the art, including: filtration, centrifugation, recrystallization, distillation, adsorption, chromatographic methods, fractionation, etc.
In some embodiments, the vegetable source is first dried and ground before being treated in the water / alcohol solution.
In some embodiments, the saponin material is extracted from a vegetable source that follows a method that comprises: 1. treating the vegetable source in a water solution: alcohol from 40:60 to 60:40 for a period of time and under conditions that allow the extraction of saponin material from said plant source to said solution, as defined above in this document; 2. optionally, evaporate the saponin-containing solution to obtain a solid material containing saponin; and 3. optionally, purifying said solid material containing saponin.
In some modalities, the plant source is one or both of Camellia oleifera and Sapindus mukorossi. In some embodiments, the plant source is Sapindus mukorossi and the saponin material is extracted from the nutshell. In other modalities, the vegetable source is Camellia oleifera and in some modalities the saponin material is extracted from the defatted seed flour of Camellia oleifera.
As mentioned above, the composition of the invention comprises at least one saponin material and an extract from at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture of extracts thereof. It should be understood that the extract can be an extract from more than one plant selected from Lonicera, Populus, Salix and Wasabia and that each plant can be selected from the same genus or from a different genus. It should be further understood that the present invention additionally contemplates a composition comprising mixtures of extract, prepared and formulated individually or prepared in a bowl from a mixture of vegetable source (vegetable parts).
The genus "Lonicera" contains a group of arched shrubs or twinned vines in the Caprifoliaceae family that are commonly known as Honeysuckles. Known species include Lonicera periclymenum (European or Woodbine Honeysuckle), Lonicera japonica (Japanese Honeysuckle, White Honeysuckle or Chinese Honeysuckle) and Lonicera sempervirens (Coral Honeysuckle, Trumpet Honeysuckle, or Woodbine Honeysuckle).
In some modalities, the Lonicera extract is an extract of Lonicera periclymenum (European Honeysuckle or Woodbine type), Lonicera japonica (Japanese Honeysuckle, White Honeysuckle or Chinese Honeysuckle) and / or Lonicera sempervirens (Coral Honeysuckle, Honeysuckle Coral, Honeysuckle Trumpet, or Honeysuckle of the Trumpet, or Honeysuckle of the Trumpet type Woodbine). In other modalities, the extract of Lonicera is an extract of Lonicera japonica (Japanese Honeysuckle, White Honeysuckle or Chinese Honeysuckle).
The genus "Populus" comprises species of deciduous flowering plants in the family Salicaceae. Species of this genus include aspen (for example, Populus adenopoda, Populus alba, Populus grandidentata, Populus sieboldii, Populus tremula and Populus tremuloides), and white willow (for example, Populus deltoids, Populus fremontii and Populus nigra).
In some embodiments, Populus extract is an aspen extract (for example, Populus adenopoda, Populus alba, Populus grandidentata, Populus sieboldii, Populus tremula and Populus tremuloides), and / or white willow (for example, Populus deltoids, Populus fremontii and Populus nigra). In other modalities, Populus extract is an aspen extract selected from Populus adenopoda, Populus alba, Populus grandidentata, Populus sieboldii, Populus tremula and Populus tremuloides. In other modalities, the extract is Populus tremuloides.
The genus "Salix" that belongs to the Salicaceae family specifically includes the species Salix herbacea, Salix babylonica, Salix alba, Salix x sepulcralis (weeping willow), and also includes, among others, the species Salix aegyptiaca, Salix alaxensis, Salix alba, Salix amplexicaulis, Salix amygdaloides, Salix ansoníana, Salix apennina, Salix apoda, Salix appendiculata, Salix arbuscula, Salix arctica,
Salix argyracea, Salix arizonica, Salix armenorossica, Salix atrocinerea, Salix aurita, Salix babylonica, Salix balfouriana, Salix barclayi, Salix bebbiana, Salix bi color, Salix bikouensis, Salix bonplandiana, Salix boothii, Salix brachycarpa, Salix breviserrata, Salix breviserrata burqinensis, Salix caesia, Salix calcicola, Salix calliantha, Salix canariensis, Salix candida, Salix cantabrica, Salix capensis, Salix capitata, Salix caprea, Salix capusii, Salix carmanica, Salix caroliniana, Salix caspica, Salix cavaleriei, Salix chaenomeloides, Salix chaenomeloides, Salix chaenomeloides, Salix chaenomeloides Salix cordata, Salix delnortensis, Salix discolor, Salix drummondiana, Salix eastwoodiae, Salix eriocephala, Salix excelsa, Salix exigua, Salix fargesii, Salix floderusii, Salix fluviatilis, Salix foetida, Salix fragilis, Salix geyeriana, Salix gilgra, Salix gilgra , Salix glaucosericea, Salix gooddingii, Salix gordejevil, Salix graciliglans, Salix gracilistyla, Salix hastata, Salix hegetschweileri, Salix helvetica , Salix herbacea, Salix hookeriana, Salix humboldtiana, Salix humilis, Salix hylematica, Salix integra, Salix irrorata, Salix japonica, Salix jejuna, Salix jepsonii, Salix jessoensis, Salix koreensis, Salix koriyanagi, Salix laevigata, Salix laevigata, Salix lanata, Salix lanata, Salix lanata lasiolepis, Salix lemmonii, Salix ligulifolia, Salix linearistipularis, Salix longiflora, Salix longistamina, Salix lucida, Salix lutea, Salix magnifica, Salix matsudana, Salix maximowiczii, Salix medwedewii, Salix melanopsis, Salix microstinya, Salix micha Salix mucronata, Salix muscina, Salix myricoides, Salix myrsinifolia, Salix myrsinites, Salix myrtilloides, Salix neowilsonii, Salix nigra, Salix nivalis, Salix orestera, Salix paraplesia, Salix pauciflora, Salix pedicellata, Salix pellita, Salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita, salix pellita , Salix phylicifolia, Salix planifolia, Salix polaris, Salix prolix, Salix purpurea, Salix pyrenaica, Salix pyri folia, Salix pyr oli folia, Salix rehderiana, Salix repens, Salix reptans, Salix reticulata, Salix retusaides, Salix retusoides, Salix rorida, Salix rosmarinifolia, Salix sajanensis, Salix salviifolia, Salix schwerinii, Salix scouleriana, Salix sericea, Salix serif, Salix serisia, Salix serisia , Salix sitchensis, Salix siuzevii, Salix starkeana, Salix subopposita, Salix subserrata, Salix suchowensis, Salix sungkianica, Salix taxi folia, Salix tenuijulis, Salix tetrasperma, Salix triandra, Salix turanica, Salix turfacea, Salix udensis. Salix variegata, Salix vestita, Salix viminalis, Salix vulpina, Salix waldsteiniana, Salix wallichiana, Salix wilhelmsiana, Salix wilsonii, Salix yezoalpina.
In some embodiments, the extract of a species that belongs to the genus Salix is Salix alba. In some modalities, the extract of a species that belongs to the genus Salix is extracted from the leaves and in some modalities it is extracted from the bark of the plant.
The "Wasabia" genus that belongs to the Brassicaceae family includes, among others, the species Wasabia japonica, Wasabia koreana, Wasabia tetsuigi, Wasabia tenuis, Wasabia bracteata, Wasabia okinosimensis, Wasabia pungens, Wasabia thibeticum and Wasabia yunnanensis. In some embodiments, Wasabia extract is an extract of Wasabia j aponica, Wasabia koreana, Wasabia tetsuigi, Wasabia tenuis, Wasabia bracteata, Wasabia okinosimensis, Wasabia pungens, Wasabia thibeticum and / or Wasabia yunnanensis. In other embodiments, the Wasabia extract is an extract of Wasabia japonica.
The extract from the plant sources identified above can be obtained from any part of the plant, including leaves, stems, roots, bulbs, flower and fruit (including the skin, flesh and seed of the fruit). In some embodiments, the extracts are obtained from Sapindus mukorossi nut, Camellia oleifera seed flour, Lonicera japonica flower and buds, Wasabia japonica root, Populus tremuloides bark or a combination thereof. In other modalities, each of the plant extracts is obtained commercially.
In some embodiments, the composition of the invention comprises a saponin material and at least one extract selected from Lonicera japonica, Populus tremuloides, Salix alba and Wasabia japonica.
Generally, in the compositions of the invention, the weight / weight (w / w) ratio between the saponin material and each of the extracts of a species belonging to the genus Lonicera,
Populus, Salix or Wasabia can vary independently from 1: 100 to 100: 1 (saponin material: species extract). In some embodiments, the weight / weight ratio between the saponin material and each of the extracts is independently about 1:10 to 1: 100. In some embodiments, the weight / weight ratio between the saponin material and each of the extracts is independently about 1: 100, 1:90, 1:80, 1:70, 1:60, 1:50, 1 : 40, 1:30, 1:20, 1:15, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1: 5, 1: 4, 1: 3, 1: 2 , 1: 1, 2: 1; 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1, 60: 1, 70: 1, 80: 1, 90: 1 or about 100: 1.
In some embodiments, the weight of the saponin material may be in excess compared to the other active components in the final composition.
In some embodiments, the amount of the saponin material in the total weight of the solid materials in the composition is in the range of 0.33 to 99% by weight.
In some embodiments, the amount of the saponin material in the total weight of the composition is in the range of 1 to 30% by weight. In another aspect of the present invention, a composition is provided that comprises at least one saponin material, a salicylate and / or salicin (2- (hydroxymethyl) phenyl-β-D-glycopyranoside).
As used herein, "salicylate" refers to a derivative of salicylic acid (2-hydroxybenzenecarboxylic acid), which can be obtained naturally or synthetically. The term encompasses the salt (base addition salt) form of salicylic acid as well as esters and amides of salicylic acid. Salts of salicylic acid can be amine or metal salts, derivatives of alkaline earth or alkaline metals or organic amines and ammonia. According to some embodiments, the composition comprises salicylate esters such as methyl salicylate, ethyl salicylate, propyl salicylate, butyl salicylate, pentyl salicylate, hexyl salicylate, cyclohexyl salicylate, benzyl salicylate and others.
In some embodiments, at least one salicylate is derivable from at least one plant source. In additional modalities, the plant source is at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture of them, as defined above in this document.
In some embodiments, at least one salicylate is derivable from a plant selected from slow birch (sweet birch), pendulous birch (white birch), Filipendula ulmaria (ulmária), Gaultheria procumbens (wintergreen), Populus balsamifera (poplar balm) , Populus nigra (black poplar), Populus candicans (gilead balm), Salix alba (white willow) and Viburnum prunifolium (black hawthorn).
In some embodiments, the composition comprises a saponin material and at least one of Lonicera japonica extract, Wasabia japonica extract and / or Populus tremuloides extract, and salicylate.
In some embodiments, the composition of the invention additionally comprises one or more of arbutin (obtainable from bearberry), leontopodic acid (obtainable through edelweiss extraction) and chlorogenic acid (obtainable through extraction of green tea, apple, potato, lonicera and other sources).
The compositions of the invention can be prepared by any method commonly used to prepare a composition of materials. For example, the components of the composition can be added as solids and mixed together, or one of the components can be added to the other in the form of a solution that can, if desired, be evaporated or lyophilized after mixing to obtain a homogeneous solution.
As will be further demonstrated below, the compositions of the invention exhibit antimicrobial, non-tearing, surface active, foaming, cleaning, antioxidant, wetting and softening properties that make the compositions suitable for a variety of applications in the fields of, for example, cosmetics , therapeutic, foodstuffs and how to conserve material. The composition of the invention can thus be formulated in a variety of formulations, such as a cosmetic formulation, a therapeutic formulation, an antimicrobial formulation, a food additive formulation and a preservative formulation. Each of the aforementioned formulations may additionally comprise an excipient, diluents or carrier suitable for the particular application, together with at least one additional additive as disclosed herein.
In another aspect, the invention provides a cleaning or cosmetic formulation comprising at least one saponin material and an extract from at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture of extracts from as defined in the various modalities above.
The cosmetic / cleansing formulations according to the invention are typically formulated in a form adapted for topical application that comprises a dermatologically or cosmetically accepted medium, namely a medium that is suitable for application to the skin of an individual (human or non-human). The medium may be in the form of an aqueous or hydroalcoholic solution, an oil-in-water or water-in-oil emulsion, a microemulsion, anhydrous or aqueous gels, serum or a dispersion of vesicles, a plaster, cream, spray, ointment, ointment, lotion, gel, solution, suspension or any other cosmetically acceptable forms known. The formulation can alternatively be formulated for application to human skin, hair, eyelashes, eyebrows or nails.
In addition, the formulation may contain other standard additives such as an emollient, moisturizer, thickener, emulsifier, neutralizer, coloring agent, a fragrance, absorbent or filter, preservative and / or gel forming agent such as those described below, filler such such as nylon, a sun protection agent, electrolytes, proteins, antioxidants and chelating agents.
The formulation may additionally further comprise at least one active ingredient such as active peptide ingredients, plant extracts, anti-aging agents, anti-wrinkle agents, smoothing agents, radical scavengers, UV-absorbing agents, agents that stimulate the synthesis of macromolecules dermal or energy metabolism, moisturizing agents, bactericidal agents, fungicidal agents, anti-inflammatory agents, anesthetic agents, agents that modulate pigmentation, depigmentation or cutaneous differentiation, agents that stimulate hair or nail growth.
In some embodiments, each of the aforementioned active ingredients / additives is generally present in an amount of between about 0.1 to 30%, by weight, of the total weight of the formulation.
Emollients suitable for use in a cleaning / cosmetic formulation according to the invention include, for example, optionally hydroxy substituted C8-C5Q unsaturated fatty acids and esters thereof, C1-C24 esters of C8-C3o saturated fatty acids such as myristate of isopropryl, cetyl palmitate and octyldodecylmiristate (Wickenol 142), beeswax, unsaturated and saturated fatty alcohols such as behenyl alcohol and cetyl alcohol, hydrocarbons such as mineral oils, petrolatum, squalane, fatty sorbitan esters, lanolin and derivatives of lanolin, such as lanolin alcohol, acetylated, hydroxylated and ethoxylated lanolines, cholesterol and derivatives thereof, animal and vegetable triglycerides such as almond oil, peanut oil, wheat germ oil, flaxseed oil, jojoba oil, oil of apricot kernels, walnuts, babassu nuts, pistachios, sesame seeds, rapeseed oil, oxycid oil, corn oil, peach kernel oil, sesame oil poppy seed, pine oil, castor oil, soy oil, avocado oil, safflower oil, coconut oil, hazelnut oil, olive oil, grape seed oil and sunflower seed oil and esters C1-C24 of trimer acids and dimers such as diisopropyl dimerate, diiso-stearylmalate, diiso-stearyldimerate and tri-stearyl-trimerate.
In some embodiments, the emollients used in a formulation according to the invention include isocetyl alcohol, octyl palmitate, isostearyl neopentanoate and stearyl isocetyl stearate, synthetic or natural oils selected from mineral, animal and vegetable oils, fats and waxes, fatty acid esters, fatty alcohols, alkylene glycol and polyalkylene glycol esters and ethers, fatty acids and mixtures thereof.
Emollients can be used independently or in mixtures and can be present in the composition of the present invention in an amount of about 1 to about 98% by weight, and in some embodiments they are present in an amount of about 5% about 15%, by weight, of the total formulation.
Emulsifiers suitable for use in a cleaning / cosmetic formulation according to the present invention include glyceryl and lauret 23 stearate, PEG 20 stearate, and amidopropyl dimethyl 2-hydroxyethylammonium chloride. Typical moisturizers are glycerin, petrolatum and vegetable oil.
The formulation of the invention may also contain a hydrophilic gel-forming agent. In some embodiments, the gel-forming agent is selected from among those that have a viscosity (1% aqueous solution, 20 ° C, RVT Brookfield) of at least about 4,000 mPa. According to other embodiments, the gel-forming agent has a viscosity of about 10,000 mPa or at least 50,000 mPa.
In other embodiments, hydrophilic gel-forming agents are selected from colloidal water-soluble or water-soluble polymers, such as cellulose ethers (for example, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose), polyvinyl alcohol, polyquaternium- 10, guar gum, hydroxypropyl guar gum, xanthan gum, Aloe vera gel, sarandi, carrageenan, oatmeal, starch (corn, rice, or other plants), gelatin (porcine skin), ghatti gum, gum arabic , inulin (chicory), Konjac gum, locust bean gum, malvaisco salts, pectin, quinoa extract, red seaweed, sole gum and tragacanth gum (TG).
In additional embodiments, hydrophilic gel forming agents are selected from ethyl acrylate / acrylic acid copolymers and the carboxyvinyl polymers sold by B.F. Goodrich Company under the trademark of Carbopol resins. These resins essentially consist of a cross-linked polyalkenyl polyether polyester polymer soluble in cross-linked acrylic acid with 0.75% to 2.00% of a cross-linking agent such as polyalyl sucrose or polyalyl pentaerythritol. Examples include Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981. Carbopol 934 is a water soluble polymer of cross-linked acrylic acid with about 1 polyaryl sucrose ether that has an average of about 5, 8 allyl groups for each sucrose molecule. Also suitable for use herein are hydrophobically modified crosslinked polymers of acrylic acid that have amphipathic properties available under the Trade Name Carbopol 1382, Carbopol 1342 and Pemulen TR-1. A combination of the polyalkenyl polyether crosslinked acrylic acid polymer and the hydrophobically modified crosslinked acrylic acid polymer is also suitable for use herein.
Other gel-forming agents suitable for use herein are oleogels such as trihydroxystearin and hydroxy magnesium aluminum stearate.
In some embodiments, the gel-forming agent is present in the cleaning / cosmetic formulation in an amount of about 0.01% to about 10% of the total formulation weight. In some embodiments, the formulation comprises a hydrophilic gel-forming agent in an amount from about 0.02% to about 2%. In other embodiments, the amount of the gel-forming agent is from about 0.02% to about 0.5%.
The cleaning / cosmetic formulation may further comprise a thickener, such as crosslinked maleic anhydride-alkyl vinylethers, and copolymers, commercially available as Stabilizes QM (International Specialty Products (ISP)), Carbomer, natural gums, highly polymethacrylate copolymer cross-linked, such as Microspongess 5647, which take the form of generally spherical particles of cross-linked hydrophobic polymer which have a pore size of about 0.01 to about 0.05 μm and a surface area of 200 to 300 m2 / g .
Neutralizing agents suitable for use in a cleaning / cosmetic formulation of the invention include neutralizing acid group containing hydrophilic gel forming agents, as listed herein, sodium hydroxide, potassium hydroxide, ammonium hydroxide, monoethanolamine, diethanolamine and triethanolamine and aminomethyl propanol.
In some embodiments, the cleaning / cosmetic formulation comprises one or more ultraviolet absorbing agents. Ultraviolet absorbing agents, often described as sunscreen agents, can be present in a concentration between about 1% and about 25% by weight, based on the total weight of the composition. According to some embodiments of the invention, the UV-absorbing agent constitutes between about 2% and 15% by weight. According to other embodiments, the UV-absorbing agent constitutes between about 4% and about 10% by weight. Non-limiting examples of ultraviolet absorbing agent include benzophenone-3, benzophenone-4, octyl dimethyl PABA (Padimato 0), octyl methoxy cinnamate, octyl salicylate, octocrylene, p-methylbenzylidene camphor, butyl methoxy dibenzyl methane (Parsol89) titanium dioxide, zinc oxide and mixtures thereof.
The cleaning / cosmetic formulation of the invention can be used to treat or prevent the formation of wrinkles, skin imperfections, fine lines, cracked skin, enlarged pores, loss of firmness, discoloration, aged areas, keratosis, collagen loss and other changes of the dermis and epidermis.
In a further aspect, the invention provides an antimicrobial formulation comprising at least one saponin material and at least one extract of a plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture of extracts thereof, as defined in this document.
The antimicrobial formulation of the invention is effective in reducing or eliminating a population of microorganisms or a biofilm of such microorganisms. As demonstrated in this document, the formulations of the invention provide instant and persistent antimicrobial activity against a wide spectrum of microorganisms and specifically against a wide spectrum of bacteria. The term "microorganism" refers in this document to a single cell (unicellular) organism, of cellular clusters, or without a cell (acellular) such as bacteria, fungi, yeast, mold, archaea, protists, viruses and algae.
In some modalities, the microorganism is a bacterium that is selected, in some modalities, from Bordetella pertussis, Borrelia burgdorferi, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumonia, Chlamydia psittaci, Chlamydia tractis Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Escherichia coli (E. coli), Escherichia coll Enterotoxigenic (ETEC), E. coli Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumonia, Neisseria gonorrhoeae, Neisseria meningitidis, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Stamonella typhi, Salmonella typhi, Salmonella typhi, coccus agalactiae, Streptococcus mutans, Streptococcus pneumonia, Streptococcus pyogenes, Treponema pallidum, Vibrio cholera, Vibrio harveyi and Yersinia pestis.
In some modalities, the microorganism is a fungus, selected in some modalities from Absidia corymbifera, Aj ellomyces capsulatus, Ajellomyces dermatitidis, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvatum, Arthroderma otae, Aroder , Aspergillus niger, Blastomyces dermatitidis, Candida albicans, Candida albicans var. stellatoidea, Candida dublinensis, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida pelliculosa, Candida tropicalis, Cladophialophora carrionii, Coccidioides immitis, Cryptococcus neof ormans, Cunninghamella sp. candidum, Histoplasma capsulatum, Hortaea werneckii, Issatschenkia orientalis, Madurella grisae, Malassezia furfur, Malassezia furfur complex, Malassezia globosa, Malassezia obtuse, Malassezia pachydermatis, Malassezia restricts, Malassezia slooffiae, Malassezia fodisis, Microspor
Microsporum gypseum, Microsporum gypseum complex, Microsporum gypseum, Mucor circinelloides, Nectria haematococca, Paecilomyces variotii, P. brasiliensis, Penicillium marneffei, warty Phialophora, anomala Pichia, Pichia guilliermondii, Pneumocystis jirovecii, P. boydii, Rhizopus oryzae, rubra Rodotorula, Saccharomyces cerevisiae, Scedosporium apiospermum, Schizophyllum commune, Sporothrix schenckii, Stachybotrys chartarum, Trichophyton mentagrophytes, Trichophyton mentagrophytes complex, Trichophyton mentagrophytes, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton menton, Trichophyton veron, Trichophyton, Trichophyton, Trichophyton and Trichosporon mucus.
In some modalities, the microorganism is a yeast, which is selected, in some modalities, from Candida albicans, Candida albicans var. stellatoidea, Candida dublinensis, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida pelliculosa, Candida tropicalis, Cryptococcus neoformans, Filobasidiella neoformans, Geotrichum candidum, Issatschenkia orientalis, Malasseichisierisis, Malasseichisieris, Malasseichisieri Rodotorula rubra, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin and Trichosporon mucoides.
In some modalities, the microorganism is a mold, which is selected, in some modalities, from Absidia corymbifera, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvatum, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus, Aspergillus fliger, Aspergillus fliger, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus, Aspergillus. , Cladophialophora carrionii, Coccidioides immitis, Epidermophyton floccosum, Exophiala dermatitidis, Fonsecaea pedrosoi, Hortaea werneckii, Madurella grisae, Microsporum canis, Microsporum fulvum, Microsporum gypseum, Microsporum gypseum, Microsporum gypseum, Microscopeum, marneffei, Pseudallescheria boydii, Rhizopus oryzae, Scedosporium apiospermum, Schizophyllum commune, Sporothrix schenckii, Stachybotrys chartarum, Trichophyton mentagrophytes complex, Trichophyton mentagrophytes, Trichophyton mentagrophytes, Trichophytonophyophytis osum and Trichophyton violaceum.
According to some embodiments of the invention, the antimicrobial formulations of the invention are effective against bacteria such as Escherichia coli (E. Coli), Salmonella, Staphylococcus, Saccharomyces, Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, A. niger as shown by the test antimicrobial effectiveness provided below.
In some embodiments, the antimicrobial formulations of the invention are effective in reducing, inhibiting, eliminating or preventing the growth of Staphylococcus, E. coli and salmonella.
In some embodiments, the antimicrobial formulations of the invention are effective in reducing, inhibiting, eliminating or preventing the growth of Streptococcus mutans and Vibrio harveyi.
In a further aspect, the invention provides a therapeutic formulation (pharmaceutical composition) comprising at least one saponin material and at least one extract of a plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture extracts thereof, as defined in this document.
The pharmaceutical formulation of the invention can be effective in treating and / or preventing a variety of diseases and disorders. As demonstrated below in this document, the formulations of the invention provide instant and persistent antimicrobial activity against a wide spectrum of microorganisms, as defined in this document. In some modalities, the disease or dysfunction to be treated is associated with bacterial infection, fungal infection or viral infection.
In some embodiments, the pharmaceutical composition of the invention is used in the treatment or prevention of a disease or dysfunction associated with a bacterial infection, wherein said bacterial infection is caused by a bacterium selected, without limitation, from Bordetella pertussis, Borrelia burgdorferi , Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumonia, Chlamydia psittaci, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetiichi, Enteric . coli), Enterotoxigenic Escherichia coli (ETEC), Enteropathogenic E. coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Lactobacilli, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, , Pla smodium falciparum, Plasmodium knowlesi, Plasmodium sp., Pseudomonas aeruginosa, Rickettsia rickettsii, Saccharo yces cerevisiae, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epocococcus epiderocyl, Staphylococcus epidermidylis, Staider
Streptococcus pyogenes, Treponema pallidum, Vibrio cholera, Vibrio harveyi and Yersinia pestis.
Non-limiting examples of disease or dysfunction associated with a bacterial infection include lyme disease, brucellosis, acute enteritis, ornithosis, non-gonococcal urethritis (NGU), trachoma, newborn inclusion conjunctivitis (ICN), venereal lymphogranuloma (LGV), botulism, pseudomembranous colitis, gas gangrene, acute food poisoning, anaerobic cellulitis, tetanus, diphtheria, nosocomial infections, urinary tract infections (ICU), diarrhea, meningitis, infantile meningitis, hemorrhagic colitis, hemolytic-uremic syndrome, tularemia, infections of the urinary tract upper respiratory tract, pneumonia, mycoplasma pneumonia, secondary pneumonia, bronchitis, peptic ulcer, legionary disease, B-cell gastric lymphoma, pontiac fever, leptospirosis, listeriosis, leprosy, tuberculosis, gonorrhea, neonatal ophthalmia, meningococcal disease, Waterhouse- Friderichsen, localized infection (of the eye, ear, skin, urinary, respiratory), gastrointestinal tract infection, infection central nervous system infection, systemic infection with bacteremia, joint or bone infections, endocarditis, typhoid-like salmonellosis, dysentery, colitis, salmonellosis with gastroenteritis and enterocolitis, bacillary / shigellosis, streptococcal pharyngitis, scarlet fever, rheumatic fever, impetigo and erysipelas, puerperal fever, necrotizing fasciitis, syphilis, congenital syphilis and cholera.
In some embodiments, the disease or bacterial dysfunction is associated with infections by Staphylococcus or Escherichia coli (E. coli) or salmonella; the disease or dysfunction being selected from:
Staphylococcus: coagulase positive staphylococcal infections such as localized skin infections, diffuse skin infection (impetigo), localized and deep infections, acute infectious endocarditis, septicemia, necrotizing pneumonia, toxinosis, toxic shock syndrome, staphylococcal food poisoning, implanted prosthesis infections , for example, catheters and heart valves and cystitis in women; E. coli: urinary tract infections (UTI), diarrhea, meningitis in infants, traveller's diarrhea, hemorrhagic colitis and hemolytic-uremic syndrome; Salmonella: typhoid fever-like salmonellosis, dysentery, colitis, salmonellosis, for example, with gastroenteritis and enterocolitis.
In some embodiments, the pharmaceutical composition of the invention is used in the treatment or prevention of a disease or dysfunction associated with a fungal infection, wherein said fungal infection is caused by a fungus selected, without limitation, from Absidia corymbifera, Aj ellomyces capsulatus, Ajellomyces dermatitidis, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvatum, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus flavus, Aspergillus fumigates, Aspergcesis alit, Candids, albicans, Candida albicans, Candida albicans, Candida stellatoidea, Candida dublinensis, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida pelliculosa, Candida tropicalis, Cladophialophora carrionii, Coccidioides immitis, Cryptococcus neoformans, Cunninghamella sp. , Epidermophyton floccosum, Exophiala dermatitidis, Filobasidiella neoformans, Fonsecaea pedrosoi, Geotrichum candidum, Histoplasma capsulatum, Hortaea werneckii, Issatschenkia orientalis, Madurella grisae, Malassezia furfur, Malassezia furfy, Malassezia furfy, Malassezia Malassezia sympodialis, Microsporum canis, Microsporum fulvum,
Microsporum gypseum, Microsporum gypseum complex, Microsporum gypseum, Mucor circinelloides, Nectria haematococca, Paecilomyces variotii, Paracoccidioides brasiliensis, Penicillium marneffei, Phialophora verrucosa, Pichia anomala, Pichia anomala, Schizophyllum commune, Sporothrix schenckii, Stachybotrys chartarum, Trichophyton mentagrophytes, Trichophyton mentagrophytes complex, Trichophyton mentagrophytes, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton verrucosum, Trichophyton violetum, Trichophyton violaceum, Trichophyton violaceum In some embodiments, the pathogen is a yeast.
The yeast that causes the disease or dysfunction can be selected from Candida albicans, Candida albicans var. stellatoidea, Candida dublinensis, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida pelliculosa, Candida tropicalis, Cryptococcus neoformans, Filobasidiella neoformans, Geotrichum candidum, Issatschenkia orientalis, Malasseichisierisis, Malassezia furisumi , Rodotorula rubra, Saccharomyces cerevisiae, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin and Trichosporon mucoides.
In some embodiments, the pathogen is a mold. The mold that causes the disease or dysfunction is selected from Absidia corymbifera, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvatum, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus flavus, Aspergillus, Aspergilli
Epidermophyton floccosum, Exophiala dermatitidis, Fonsecaea pedrosoi, Hortaea werneckii, Madurella grisae, Microsporum canis, Microsporum fulvum, Microsporum gypseum, Microsporum gypseum, Microsporum gypseum, Mucor circinelloides, Nectria haematoci , Scedosporium apiospermum, Schizophyllum commune, Sporothrix schenckii, Stachybotrys chartarum, Trichophyton mentagrophytes complex, Trichophyton mentagrophytes, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton verrucosum and Trichophyton violetum.
According to some embodiments of the invention, the formulations of the invention are effective against bacteria such as E. Coli, Salmonella, Staphylococcus, Saccharomyces, S. aureus, P. aeruginosa, C. albicans, A. niger as exhibited by the antimicrobial efficacy test provided below. The combination of saponins with an extract of the genus Lonicera, Populus, Salix Wasabia or a mixture of them exhibits potency that is effective against these types of bacteria in concentrations that are much less than would be required if each of the components were used individually. For example, where an exemplary formulation according to the invention comprises 10% soap, 0.2% Aspen bark extract (Populus tremuloides} and 2% saponin material, a reduction in total Salmonella counts has been demonstrated by 6 records even after only 72 hours of incubation.
According to some modalities, the formulation acts effectively as an antimicrobial agent against E. coli, S. aureus, P. aeruginosa, C. albicans and Aspergillus niger. According to some modalities, the formulation acts effectively as an antimicrobial agent against E. coli. According to some modalities, the formulation acts effectively as an antimicrobial agent against S. a ureus. According to some modalities, the formulation acts effectively as an antimicrobial agent against P. aeruginosa. According to some modalities, the formulation acts effectively as an antimicrobial agent against C. albicans. According to some modalities, the formulation acts effectively as an antimicrobial agent against Aspergillus niger. According to some modalities, the formulation acts effectively as an antimicrobial agent against Streptococcus mutans and Vibrio harveyi. According to some modalities, the formulation acts effectively as an antimicrobial agent against Streptococcus mutans. According to some modalities, the formulation acts effectively as an antimicrobial agent against Vibrio harveyi.
The pharmaceutical composition can be adapted for administration via a variety of routes including topical, oral, rectal, vaginal, transdermal, subcutaneous, intravenous, intramuscular, eye drops and intranasal. Such a pharmaceutical composition is prepared in a manner well known in the pharmaceutical art. In creating the pharmaceutical composition of the invention, the aforementioned components are usually mixed with an excipient, diluted by an excipient or included in a carrier that can be manipulated to the desired shape. Based on the particular mode of administration, the pharmaceutical composition can be formulated into tablets, pills, capsules, sachets, granules, powders, chewing gum, suspensions, emulsions and solutions.
Pharmaceutically acceptable carriers, for example, vehicles, adjuvants, excipients or diluents, are well known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier is one chemically inert to the active formulation and each of the components and one that does not have any harmful side effects or toxicity under the conditions of use.
The choice of carrier will be determined in part by the particular formulation of the invention, as well as by the particular method used to administer the composition. Consequently, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention.
Formulations suitable for oral administration may consist of (a) liquid solutions, such as an effective amount of the compound, or composition comprising the same, dissolved in diluents, such as water, saline or juice (for example, orange juice); (b) capsules, sachets, tablets, lozenges and troches, each containing a predetermined amount of the active ingredient, such as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations can include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol and polyethylene alcohols, with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the type of common soft or hard-coated gelatin that contains, for example, surfactants, lubricants and inert fillers, such as lactose, sucrose, calcium phosphate and corn starch. Tablet form may include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, talc, magnesium stearate, calcium stearate , zinc stearate, stearic acid and other excipients, dyes, diluents, buffering agents, disintegrating agents, humidifying agents, preservatives, flavoring agents and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as lozenges comprising the active formulation in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels and the like , in addition to the active formulation, such carriers as are known in the art.
The formulations of the present invention, alone or in combination with other suitable components, for example, active or non-active additives / ingredients, can be created in aerosol formulations to be administered by inhalation. These aerosol formulations can be placed in pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen and the like. They can be formulated as pharmaceuticals for non-pressurized preparations, such as in a nebulizer or an atomizer.
Formulations suitable for parenteral administration include isotonic, aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats and solutes that make the formulation isotonic with the blood of the intended container, and aqueous and non-aqueous sterile suspensions which include suspension, solubilizers, thickening agents, stabilizers and preservatives. The formulation can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol or alcohol hexadecyl, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, such as poly (ethylene glycol) 400, an oil, a fatty acid , glyceride or fatty acid ester, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose or carboxymethylcellulose, or emulsifying agents and other pharmaceutical additives.
Oils, which can be used in parenteral formulations, include synthetic, vegetable, animal or petroleum oils. Specific examples of oils include peanut, soy, sesame, cottonseed, corn, olive, petrolatum and mineral. Fatty acids suitable for use in parenteral formulations include oleic acid, stearic acid and isostearic acid. Ethyl oleate and isopropryl myristate are examples of suitable fatty acid esters. Soaps suitable for use in parenteral formulations include alkaline fatty metal, ammonium and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, olefin, aryl and alkyl sulfonates, monoglyceride sulfates, alkyl, olefin, and ether, and sulfosuccinates, (c) non-ionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-β-aminopriopionates, and quaternary ammonium salts of 2-alkyl-imidazoline, and (3) mixtures thereof.
In order to minimize or eliminate irritation at the injection site, such compositions may contain one or more non-ionic surfactants that have a hydrophilic-lipophilic balance (HLB) of about 12 to about 17. The amount of surfactant in such formulations varies from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by condensing propylene oxide with propylene glycol. Parenteral formulations can be presented in sealed single-dose or multiple-dose containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition that only requires the addition of the sterile liquid carrier, for example, water, for injections, immediately before use. Extemporaneous injection solutions and suspensions can be prepared from sterile tablets, granules and powders of the type previously described.
The active formulation is effective over a wide dosage range and can generally be administered in a pharmaceutically effective amount. It should be understood, however, that the amount of the formulation or each component of it to be administered, will be determined by a doctor, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual formulation, the age, weight and response of the individual patient, the severity of the patient's symptoms and the like.
In another aspect of the invention, the use of a formulation of the invention as defined herein is provided for the preparation of a pharmaceutical composition for treating or preventing a disease or dysfunction in a mammal (human or non-human). In some embodiments, the disease or dysfunction is associated with a bacterium, virus, fungus, yeast or mold.
As used herein, the term "treatment" or any linguistic variation thereof, refers to the administration of a therapeutic amount of the composition of the present invention that is effective in ameliorating unwanted symptoms associated with a disease, to prevent the onset of such symptoms. before they occur, to slow the progression of the disease, reduce the speed of the deterioration of symptoms, to intensify the onset of the remission period, to reduce the speed of irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, decrease the severity or cure the disease, to improve the rate of survival or faster recovery, or to prevent the form of the disease from occurring or a combination of two or more of the factors described above. The "effective amount" for purposes disclosed herein is determined by such considerations as may be known in the art. The amount can be effective in achieving the desired therapeutic effect as described above, depending, among other things, on the type and severity of the disease to be treated and the treatment regimen. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person skilled in the art will know how to properly conduct such trials in order to determine the effective amount. As is generally known, an effective amount depends on a variety of factors including the ligand's affinity for the receptor, its distribution profile in the body, a variety of pharmacological parameters such as lifetime in the body, unwanted side effects, if any, of factors such as age and gender, etc.
In yet another aspect, the invention provides a preservative formulation comprising at least one saponin material and an extract from at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia or a mixture of extracts thereof, as defined in this document.
The preservative formulation of the invention can be used to reduce, inhibit or completely eliminate a population of pathogen in a variety of consumer products, such as personal care products, industrial products, food, therapeutic and other products. As demonstrated in this document, the formulation of the invention can be used to replace chemicals currently available that are used as preservatives, some of which are known to be toxic to humans and animals, or to reduce their concentration in such products for human use or animal. The preservative formulation can be added to any such product, such as cosmetics and hygiene articles in aqueous or hydroalcoholic solution, oil-in-water or water-in-oil emulsion, aqueous or anhydrous gels, cream, ointment, lotion, gel, solution and suspension; over-the-counter pharmaceutical and therapeutic products, water-based paints, cutting oils, latex solutions, food products such as beverages, frozen foods, sweets and canned products.
In some embodiments, the formulation of the invention is an antimicrobial preservative, which attests to the ability of the formulations of the invention to suppress microbial growth, reduce microbial infestation, treat products or surfaces to improve the product's resistance to microbial infestation, reduce biofilm, prevent conversion of bacteria in biofilm, prevent or inhibit microbial infection, prevent deterioration, delay or minimize or prevent the perception of quorum sensing and delay microbial reproduction. Typically, the preservative formulation according to the invention comprises the plant / plant extract (s) and saponin in a concentration that is sufficient to prevent deterioration or growth of microorganisms, thereby extending the shelf life or life useful product.
Pathogens against which the preservative formulation can be effective include a wide spectrum of microorganisms such as bacteria, fungi, yeasts, molds, archaea, protists, viruses and algae, as listed and disclosed above in this document.
The formulation of the invention can also be used as a disinfectant or bactericidal agent. The formulations of the invention can be applied to a surface to be disinfected, including human or animal skin, by various means including washing, spraying, cleaning, etc. MODES FOR CARRYING OUT THE INVENTION
The following description is provided, together with all chapters of the present invention, in order to allow an individual skilled in the art to make use of said invention. The examples provided in this document are representative of sets of procedures employed by the inventors in carrying out aspects of the present invention. It should be noted that although these sets of procedures are exemplary of certain modalities for the practice of the invention, those skilled in the art, in the light of the present disclosure, will recognize that numerous modifications can be made without departing from the intended spirit and scope of the invention. .
The present invention is directed to a formulation comprising a saponin material and a plant extract as disclosed above in this document. GENERAL PREPARATION OF EXTRACTS
As used herein, the term "extract" refers to an active ingredient or isolated fraction of a plant through the use of a solvent or solvent system. The solvent can be chosen from water or from commonly used organic solvents such as alcohols, especially lower alcohols such as methanol, ethanol, propanol, iso-propanol and butanol; alkanes such as pentane and hexane, 40 to 60 or 60 to 80 petroleum ether; chlorinated alkanes such as dichloromethane and dichloroethane; aromatic solvents such as toluene and xylene; ethers such as diethyl ether; ethyl acetate and any other solvent commonly known to the person skilled in the art.
The extraction procedure for obtaining any of the plant extracts used in accordance with the invention, unless otherwise indicated, can be performed on any variation and set of procedures commonly used in the techniques as described, for example, in M. Casey , J. Leonard, B. Lygo, and G. Procter "Advanced Practical Organic Chemistry", 1990, Chapman & Hall, London. For example, parts of the plant can be crushed and / or ground and optionally dried before being brought into contact with the extraction solvent; extraction can be assisted by shaking or shaking, heating; extraction can be assisted by microwave and / or ultrasound; brine can be used instead of water; the solvent can be filtered and reduced under reduced pressure evaporation; filtered solids can be re-extracted to produce a second crop; and so on.
Extracts from at least one plant species of a genus selected from Lonicera, Populus, Salix and Wasabia are commercially available and can be used without further purification. For example, Populus tremuloides extract can be purchased from Active Micro Systems (USA);
Lonicera japonica can be purchased from Campo (Singapore), Salix American Botanicals (USA) and Wasabi japonica from Active concepts (Italy).
The saponin material can be similarly achieved, or it can be extracted from a plant source, as disclosed above in this document, through solvent extraction that employs aqueous alcohol. The water / alcohol solvent system that is used according to some modalities is in the range of 90:10 to 10:90. In some modalities, the water / alcohol ratio is between 70:30 to 30:70. In other modalities, the water / alcohol ratio is between 60:40 to 40:60. In other modalities, the water / alcohol ratio is between 50:50 to 40:60.
The alcohol used in the extraction is selected from methanol, ethanol, propanol, iso-propanol and butanol. According to some modalities, the solvent system used for the extraction of saponins is water / ethanol at 50:50.
According to some embodiments of the invention, saponin is extracted from Sapindus Mukorossi or Camellia oleifera through a 50:50 water / ethanol extraction solution. The extraction is performed in Sapindus Mukorossi pericarp or Camellia oleifera defatted seed flour. The extraction can continue for a period of 2 to 8 hours at a temperature above room temperature; the extraction can be carried out at an acid-neutral pH.
As can be understood, the saponin-containing extract can also contain a variety of natural products such as acyclic sesquiterpene oligoglycosides (ASOGs).
EXAMPLES Example 1: Sapindus Mukorossi and Camellia oleifera extractions through the use of various ethanol / water mixtures 100 grams of Sapindus Mukorossi dry pericarp extract from Sapindus Mukorossi were added to 400 ml of water / ethanol at 30:70 or 50: 50 or 70:30 (w / w) on a shaker (Innova 4000 incubator shaker, New Brunswick scientific Edison, NJ USA, 183 rpm), for two hours. The stirrer was heated to 60 ° C. The solution was filtered through Whatman 1 (Qualitative 110 mm 0 x 100 Circles). Then, the water mixture was expelled through a Spray Dryer (SD-05, LabPlant, UK, pump rate: 0.01, inlet temperature 120 ° C, powder temperature 70 ° C), and a powder white-brown was obtained (12.5 to 17% yield). 100 grams of Camellia oleifera seed extract from Camellia oleifera were dipped in 400 ml of water / ethanol at 50:50 (%, by weight /%, by weight) in an agitator (Innova 4000 incubator shaker, New Brunswick scientific , Edison, NJ USA, 183 rpm), for two, four or six hours. The stirrer was heated to 60 ° C. The solution was filtered through Whatman 1, Qualitative 110 mm 0 x 100 Circles). Then, the water mixture was expelled through a Spray Dryer (SD-05, LabPlant, UK, pump rate: 0.01, inlet temperature 120 ° C, powder temperature 70 ° C), and white powder -brown was obtained. The yield was measured between 17 and 22%. Example 2: Extraction of Sapindus Mukorossi through 50:50 water / ethanol mixtures 100 grams of dry Sapindus Mukorossi pericarp were added to 400 ml of 50:50 (w / w) water / ethanol in an agitator (incubator shaker) Innova 4000, New Brunswick scientific Edison, NJ USA, 183 rpm), for two, four or six hours. The stirrer was heated to 40 ° C. The solution was filtered through Whatman 1 (Qualitative 110 mm 0 x 100 Circles). Then, the water mixture was expelled through a Spray Dryer (SD-05, LabPlant, UK, pump rate: 0.01, inlet temperature 120 ° C, powder temperature 70 ° C), and a powder white-brown was obtained. Example 3: Preparation of a composition comprising saponins 20 g of Sapindus Mukorossi solid (extract prepared using the water / ethanol solvent system (50:50) according to Example 2) was dissolved in a phosphate buffer. A mixture of Wasabia japonica extract / Populus tremuloides extract / Lonicera japonica mixture 1: 1: 1 (in this document "WPL") was dissolved in a phosphate buffer. The mixtures were stirred and then diluted in a buffer phosphate to obtain seven compositions: 0: 0, 0.2: 2, 0.2: 10, 0.2: 20, 0.1: 20, 0.05: 20, 0.01: 20, 0:20 % by weight of solutions (1: 1: 1 WPL / Sapindus Mukorossi extract). The solutions were heated overnight to 50 ° C to obtain sterile solutions. Example 4: Effect demonstrated in a test of challenge
The tests were conducted by adding: (a) sterile solutions of the compositions prepared in Example 3, (b) a sterile 20% solution by weight of Sapindus Mukorossi extract and (c) a sterile solution of the WPL mixture 1: 1: 1 of Example 3 is an inoculum of suitable microorganisms (bacteria and yeasts), as described below. The solutions thus prepared were stored at 37 ° C for bacteria or 30 ° C for yeast. Using serial dilutions and plate counts, aliquots were taken during the incubation period to determine the microorganism count.
Means and reagents used: 100 mM phosphate buffer with pH = 5.5 (sterile), TSYE (30 g / 1/1 triptych soy broth + 5 g / 1 yeast extract) were added to a solid medium of 2% agar, PDB (24 g / 1 of potato dextrose broth + 0.2 g / 1 of chloramphenicol) was added to a solid medium of 2% agar and a diluent (a sterile 0.9 solution % sodium chloride and 0.1% peptone) was used when indicated.
The tested organisms were ATCC 14028 from Salmonella typhimurium, EDL933 from Escherichia coli, MRSA strain Newman D2 ATCC 25904 from Staphylococcus aureus and ATCC 11777 from Saccharomyces cerevisiae. The three bacteria were grown overnight in TSYE, on an incubator shaker at 37 ° C. Yeast cells were grown overnight in PDB, on an incubator shaker at 30 ° C. The culture media overnight was washed twice with the diluent by centrifugation and each organism was transferred to 5 ml of the phosphate buffer containing different extract combinations to yield 105 / ml. The test tubes were incubated at 37 ° C for bacteria or 30 ° C for yeast. Aliquots were taken during the incubation period in order to determine the microorganism count. The numbers in the table are the averages of two separate experiments. Each treatment was repeated three times.
Table 1: total count of different microorganisms depending on the concentrations of Sapindus mukorossi extract and cocktail of preservatives
As can be seen from Table 1, except for the case of Staphylococcus, the Mixture of WPL extract alone or Sapindus Extract alone did not reduce the total microorganism count below 1,000. Regarding Staphylococcus, the WPL Extract itself reduced the count by a factor of 10 while the Sapindus extract reduced it by 3 orders of magnitude. Thus, in general, the combination of the mixture of WPL extract and Sapindus extract reduced the total microorganism count below 10. These surprising results indicate a synergistic effect between the Sapindus extract and the preservative cocktail. Example 5: Antimicrobial Efficacy Test (USP 32, 2009) The test was performed in accordance with the requirements of US Pharmacopoeia 32 2009, (51) Antimicrobial Efficacy Test.
The test was conducted on 100 g of samples of a shampoo formulation comprising 81.1% water, 10% soap nut extract, 4% Betaine, 2% Phospholipon 50 (Lipoid), 2% Gum guar, 0.3% Xanthan gum, 0.3% Aspen extract (Active Micro Sycaules), 0.3% fragrance mixture (Expressions Parfumees). In this document, this formulation is called the MC-6 formulation.
Each sample was inoculated separately by one of the five test organisms. The inoculated containers were incubated at 25 ° C together with an inoculated sample. The number of surviving microorganisms was monitored periodically during a 4-week incubation and the colony-forming units (CFU) - were counted by a plate counter.
The microorganisms tested were: 1. ATCC 8739 from E. coli 2. ATCC 6538 from Staphylococcus aureus 3. ATCC 9027 from Pseudomonas aeruginosa 4. ATCC 10231 from Candida albicans 5. ATCC 16404 from Aspergillus niger
Table 2: total count for different microorganisms after contact with the MC-6 formulation
As can be seen from Table 2, formulation MC-6 reduced the total counts of all tested microorganisms to below 10 after 2 weeks of incubation and prevented regrowth for at least two additional weeks. The uncontaminated sample remained uncontaminated. Example 6: Antimicrobial Efficacy Test (USP 32, 2009) - redesafio The test was performed according to the requirements of US Pharmacopoeia 32 2009, (51) Antimicrobial Efficacy Test. The test was conducted on 100 g of samples that were used previously in the challenge test and showed a total count of less than 10 CFU / g after four weeks. Each sample was reinoculated separately by one of the same five test microorganisms.
The inoculated containers were incubated at 25 ° C together with an inoculated sample. The number of surviving microorganisms was verified after a 4-week incubation.
Table 3: total count for different microorganisms reinoculated in the MC-6 formulation
As can be seen from Table 3, formulation MC-6 reduced the total counts of all inoculated microorganisms tested to below 10 after 4 weeks of incubation. The uncontaminated sample remained uncontaminated. Example 7: Identification of the active fraction in frog nut extract in synthetic soap
Means and reagents used: citric acid buffer- Na2HPO4 (150 mM with pH = 5.6) and TSYE (30 g / 1 triptych soy broth + 5 g / 1 yeast extract) were added to a solid medium of 2% agar and a diluent (a sterile 0.1% peptone solution) was used where indicated. The tested organisms were ATCC 14028 of Salmonella typhimurium.
The bacteria were grown overnight in TSYE on an incubator shaker at 37 ° C. The culture media overnight was washed twice with the diluent by centrifugation and the organisms were transferred to 5 ml of the citric acid buffer-Na2HPC> 4 containing different combinations of soap, Aspen bark extract (Populus tremuloides ) and saponin to yield 105 CFU / ml. 10% Soap (Ammonium Lauryl Sulfate (6.6%) + Cocamidopropyl Betaine (3.3%)) was added with 0.1% Aspen Shell Extract and one of (1) 2% soap nut extract , or (2) 2% fraction of saponin (Soluble in Ethyl acetate) from the soap nut extract, or (3) 2% fraction of ASOGS (water soluble) from the soap nut extract. The test tubes were incubated at 30 ° C. Aliquots were taken during the incubation period to determine the microorganism count. The numbers shown in Table 4 are the average of two separate experiments. Each treatment was repeated three times.
Table 4: total count for Salmonella in soap that contains different fractions of the soap nut extract
As can be seen from Table 4, the combination of 10% Soap with 0.2% Aspen bark extract (Populus tremuloides) and 2% of the saponin fraction reduced the total Salmonella counts by 6 records after just 72 hours of incubation. Example 8: Reduction of the concentration of Aspen bark extract (Populus tremuloides)
Means and reagents used: 100 mM phosphate buffer with pH = 5.5 and TSYE (30 g / 1 triptych soy broth + 5 g / 1 yeast extract) were added to a solid medium of 2% agar , PDB (24 g / 1 of potato dextrose broth + 0.2 g / 1 of chloramphenicol) was added to a solid medium of 2% agar and a diluent (a sterile 0.1% peptone solution) was used where indicated.
The tested organism was ATCC 14028 from Salmonella typhimurium. The bacteria were grown overnight in TSYE on an incubator shaker at 37 ° C. The culture media overnight was washed twice with the diluent by centrifugation and the organisms were transferred to 5 ml of the phosphate buffer containing different combinations of soap nut extract (10% by weight of solids) ) and different concentrations of Aspen bark extract (Populus tremuloides') to yield 105 CFU / ml. The test tubes were incubated at 37 ° C for 14 days. Aliquots were taken during the incubation period to determine the microorganism count. The numbers shown in Table 5 are the averages of two separate experiments. Each treatment was repeated three times
Table 5: total Salmonella typhimurium counts as a function of concentration
As can be seen from Table 5, the preservative effect of the Aspen bark extract (Populus tremuloides) was quantitative and even as low as 0.1% caused a reduction of 4 records in the total Salmonella counts. Example 9: Testing different Saponins with synthetic soap
Means and reagents used: 150 mM of citric acid buffer-Na2HP04 with pH = 5, β and TSYE (30 g / 1 of triptych soy broth + 5 g / 1 of yeast extract) were added to a solid agar medium 2% and a diluent (a sterile 0.1% peptone solution) was used where indicated.
The tested organism was ATCC 14028 from Salmonella typhimurium. The bacteria were grown overnight in TSYE on an incubator shaker at 37 ° C. The culture media overnight was washed twice with the diluent by centrifugation and the organisms were transferred to 5 ml of the citric acid buffer-Na2HP04 which contains different combinations of soap, Aspen bark extract and saponin or just Aspen bark to yield 105 CFU / ml. 10% Soap (Ammonium Lauryl Sulfate (20%) + cocamidopropyl betaine (10%)) was added with 0.2% Aspen bark extract (Populus tremuloides) and one of (1) 1% tea saponin , (2) 2% soap nut extract. The test tubes were incubated at 30 ° C. Aliquots were taken during the incubation period to determine the microorganism count. The numbers shown in Table 6 are the average of two separate experiments. Each treatment was repeated three times.

Table 6: total Salmonella counts in soap containing different saponins
As can be seen from Table 6, the combination of 10% Soap with 0.2% Aspen bark extract (Populus tremuloides) and 1% tea saponin or 2% soap nut extract reduced the counts Salmonella totals to below 10 even after just 72 hours of incubation. Example 10: Reduction of the amount of Aspen bark extract (Populus tremuloides,) in synthetic soap
Means and reagents used: 150 mM of citric acid-NaaHPCh buffer with pH = 5.6 and TSYE (30 g / 1 triptych soy broth + 5 g / 1 yeast extract) were added to a solid agar medium 2%, PDB (24 g / 1 of potato dextrose broth +0.2 g / 1 of chloramphenicol) was added to a solid medium of 2% agar and a diluent (a sterile 0.1% solution of peptone) was used where indicated.
The tested organisms were ATCC 14028 from Salmonella typhimurium and ATCC 16404 from Aspergillus niger. The bacteria were grown overnight in TSYE on an incubator shaker at 37 ° C. The fungi were grown on PDB + agar for three weeks in an incubator at 30 ° C and harvested with conidia in 0.15% Tween 80. The culture media were washed twice with the diluent by centrifugation and the organisms were transferred to 5 ml of the citric acid buffer-Na2HP04 which contains different combinations of soap, preservative and saponin to yield 105 CFU / ml. Soap (ammonium lauryl sulfate (20%) + cocamidopropyl betaine (10%)) was added to 10% with 2% soap nut extract and varying amounts of Aspen shell extract (Populus tremuloides). The test tubes were incubated at 30 ° C for bacteria or 24 ° C for fungi. Aliquots were taken during the incubation period to determine the microorganism count. The numbers presented in Table 7 are the average of two separate experiments. Each treatment was repeated three times.
Table 7: total Salmonella and
Aspargillus in soap that contains varying concentrations of Aspen bark extract (Populus tremuloides). As can be seen from Table 7, the amount of Aspen bark extract (Populus tremuloides) can be reduced to as little as 0.1%. Even in that reduced amount the total Salmonella counts were reduced to below 10. The combination of soap and 2% soap nut saponin alone was sufficient to reduce the total Aspergillus counts to below 10. Example 11: Component determination active in the preservative formulation Means and reagents used: 100 mM phosphate buffer with pH = 5.5 and TSYE (30 g / 1 triptych soy broth + 5 g / 1 yeast extract) were added to a solid medium of 2% agar and PDB (24 g / 1 of potato dextrose broth + 0.2 g / 1 of chloramphenicol) was added to a solid medium of 2% agar and a diluent (a sterile solution of 0.1 % peptone) was used where indicated.
The tested organisms were ATCC 14028 from Salmonella typhimurium and ATCC 11777 from Saccharomyces cerevisiae. The bacteria were grown overnight in TSYE on an incubator shaker at 37 ° C. Yeast cells were grown overnight in PDB on an incubator shaker at 30 ° C. The culture media overnight was washed twice with the diluent by centrifugation and each organism was transferred to 5 ml of the phosphate buffer containing different combinations of soap nut (10% by weight of solids) and Aspen bark extract (Populus tremuloides), Wasabi extract (Wasabia japonica) or Japanese Honeysuckle extract (Lonicera Japonica) in 0.7%, by weight, to yield 105 CFU / ml. The test tubes were incubated at either 37 ° C for bacteria or 30 ° C for yeast. Aliquots were taken during the incubation period to determine the microorganism count. The numbers presented in Table 8 are the means of two separate experiments. Each treatment was repeated three times.

Table 8: total Salmonella counts depending on the combination of preservative and soap nut extract (10%, by weight, of solids).
As can be seen from Table 8, the soap nut extract (10% by weight of solids) alone or the different plant extracts alone, did not reduce the salmonella count. Only the combination of soap nut extract (10% by weight of solids) with a natural plant extract such as Aspen shell extract (Populus tremuloides) caused the total microorganism count to drop below 10. These results surprising results indicate a synergistic effect between soap nut extract (10% by weight of solids) and Aspen bark extract (Populus tremuloides). Example 12: Determination of in vivo efficacy
The effectiveness of formulations of the invention as antimicrobial agents in vivo can be tested in vitro or in vivo by a variety of methods known in the art for testing antimicrobial activity. See, for example, the methods discussed in this document and used throughout all examples. Various assays can be employed in accordance with the present invention in order to determine the degree of antimicrobial activity of a compound of the invention such as cell culture, animal models and administration to human subjects. The assays described in this document can be used to analyze microbial growth over time to determine the growth characteristics of a microbe in the presence of a formulation of the invention.
A microbe and a formulation of the invention are added to a permissive cell line (eg, primary cells, transformed cell lines, patient tissue samples, etc.) or growth medium (eg, LB agar / agar / agar / YT broth, agar / blood, etc.). The growth / infection of the microbe can be compared to the growth / infection of the microbe in the absence of the formulation of the invention. The antimicrobial activity of the formulation of the invention is demonstrated by a decrease in the growth / infection of the microbe in the presence of the formulation of the invention. Any method known in the art can be used to determine growth / infection, including, but not limited to, immunofluorescent staining, immunoblot or detection of a specific microbe nucleic acid (for example, by in situ hybridization, or after cell lysis through analysis RT-PCR or Southern blot), visual / microscopic inspection for cytopathic effect of growth infection (for example, for microbes that are viruses, cell rounding, cell shedding, cell lysis, multinucleated syncytia formation), microbe titration (by example, plaque forming units, colony forming units, etc.), number of plaque colonies.
The microbe and the formulation of the invention can be added to the cells or the growth medium at the same time or, alternatively, the microbe can be added to the cells or the growth medium before the formulation of the invention is added. As may be required, the formulation of the invention can be added to the cells or the growth medium before the microbe is introduced into the cells or the growth medium.
A microbe and a formulation of the invention can be administered to animal subjects susceptible to infection with the microbe. The incidence, severity, duration, microbe load, infection mortality rate, etc., can be compared to the incidence, severity, duration, microbe load, infection mortality rate, etc., observed when subjects are given the microbe alone (in the absence of a formulation of the invention). The antimicrobial activity of the formulation of the invention is demonstrated by a decrease in the incidence, severity, duration, microbe load, mortality rate from infection, etc., in the presence of the formulation of the invention. The microbe and the formulation of the invention can be administered to the animal subject at the same time, or one after the other.
The growth rate of the microbe can be tested using a sample of cell culture medium or clinical / biological fluid samples (for example, nasal aspiration, throat smear, sputum, bronchial-alveolar lavage, urine, saliva, blood or serum). human or animal subjects at multiple post-infection time points, both in the presence and absence of a formulation of the invention and measuring microbe levels. In specific cases, the growth rate of a microbe can be analyzed by assessing the presence of a microbe in a sample after growth in cell culture, growth in a permissible growth medium, or growth in a subject using any well-known method in technique, for example, but without limitation, immunoassay (eg, ELISA; for discussion in relation to ELISAs see, for example, Ausubel et al.r eds., 1994, Current Protocols in Molecular Biology, Volume 1, John Wiley and Sons , New York 11.2.1), immunofluorescent staining, or immunoblot analysis using an antibody that immunospecifically recognizes the microbe to be analyzed, or detection of a specific microbe nucleic acid (for example, through RT-PCR or Southern analysis blot, etc.).

权利要求:
Claims (9)
[0001]
1. COSMETIC OR CLEANING COMPOSITION, for topical application and having microbial activity, characterized by comprising at least one material isolated from a natural source containing saponin and an extract from at least one plant species of a genus selected from Lonicera, Populus and Wasabia or a mixture thereof, the natural source containing saponin being Camellia oleifera, Sapindus mukorossi or any mixture thereof, the Lonicera extract being an extract of Lonicera japonica; Populus extract being an extract of Populus tremuloides; Wasabia extract being an extract of Wasabia japonica; the composition comprising at least one saponin material and said Lonicera extract, or at least one saponin material and said Populus extract, or at least one saponin material and said Wasabia extract ..
[0002]
2. COMPOSITION according to claim 1, characterized in that the saponin material is at least one saponin compound obtained naturally, at least one extract containing saponin and a mixture thereof.
[0003]
3. COMPOSITION according to either of claims 1 or 2, characterized in that the saponin material is obtained by extraction from a plant source, said extraction process being carried out by water, alcohol or a water / alcohol solution .
[0004]
4. COMPOSITION, according to claim 3, characterized in that the water / alcohol solution has a water: alcohol ratio between 80:20 to 20:80, preferably 60:40 to 40:60, more preferably 70:30 to 30 : 70 or 50:50.
[0005]
COMPOSITION according to any one of claims 1 to 4, characterized in that the saponin material is extracted from a plant source that follows a method comprising: a. treat the plant source in a water: alcohol ratio from 40:60 to 60:40, preferably the water: alcohol ratio is 50:50, for a period of time and under conditions that allow the saponin material to be extracted said plant source in said solution; B. optionally, evaporate the saponin-containing solution to obtain a solid material containing saponin; and c. optionally, purifying said solid material containing saponin.
[0006]
6. COMPOSITION, according to claim 3, characterized in that said extraction process is carried out by water.
[0007]
7. COMPOSITION according to any one of claims 1 to 6, characterized by the weight ratio between at least one saponin material and the extract of at least one plant species of a genus selected from Lonicera, Populus, Wasabia or a mixture thereof is between about 1: 100 to about 100: 1, preferably between 1: 1 and 10: 1.
[0008]
8. CONSUMER PRODUCT, characterized in that it comprises the composition as defined in any one of claims 1 to 7.
[0009]
CONSUMER PRODUCT according to claim 8, characterized in that the product is selected from the group consisting of a preservative formulation, an antimicrobial formulation, a pharmaceutical composition, a disinfectant and a cosmetic product.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US9474283B2|2016-10-25|Formulations comprising saponins and uses thereof

---

KR20110131498A|2011-12-07|Extracted from the shell containing the antimicrobial silver ions in alkaline solution and its composition, including manufactured

---

KR20100135871A|2010-12-27|Active ingredient that stimulates the proliferation and/or activity of fibroblasts

---

WO2011036786A1|2011-03-31|Stress-alleviating agent comprising plant-derived polyamine-containing extract as active ingredient

---

TW201136614A|2011-11-01|Paxillin stimulating compositions and cosmetic uses thereof

---

KR20190085136A|2019-07-17|Compounds useful for the treatment and / or care of skin, hair, nails and / or mucosa

---

KR101754463B1|2017-07-10|COSMETIC COMPOSITIONS CONTAINING the plants extract of Cyperaceae AND PREPARING METHOD OF THE SAME

---

EP3451836B1|2021-08-25|Compositions of saponins and plant extracts

---

JP4472428B2|2010-06-02|Antibacterial agent

---

KR101433823B1|2014-08-27|External Composition for Skin Using an Extract or a Fraction of Padina arborescens

---

JP4097300B2|2008-06-11|Antiallergic agent

---

US20210275939A1|2021-09-09|Marsdenia cundurango creeper extracts, cosmetic compositions comprising them and cosmetic uses of same

---

KR101917645B1|2018-11-13|Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract

---

KR20140013796A|2014-02-05|Cosmetic composition comprising of gingenoside f1 for improving inflammatory diseases

---

JP5477731B2|2014-04-23|Melanin inhibitor, whitening agent, collagenase inhibitor, skin preparation, oral composition and food

---

JP7033160B2|2022-03-09|Vitamin D-like agent

---

JP5890955B2|2016-03-22|Pinpinella saxifrage extract

---

KR20170040659A|2017-04-13|Composition comprising fermented extract of Halophilic microorganism

---

JP2020128382A|2020-08-27|Vitamin d-like active agent

---

KR101645355B1|2016-08-04|Skin external composition for improving atopic dermatitis containing extracts or fractions of allium hookeri as active ingredient

---

KR20100041258A|2010-04-22|Novel use of js-1 thereof

---

WO2020178830A1|2020-09-10|Argan extracts for the treatment of dermatological conditions

---

KR20160114304A|2016-10-05|Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient

---

JP2013129615A5|2015-01-22|

同族专利:

---

公开号 | 公开日

---

KR20140019307A|2014-02-14|

---

IL226778A|2019-05-30|

---

EP2648742B1|2019-04-24|

---

CN103347529B|2016-10-26|

---

US20130295204A1|2013-11-07|

---

EP2648742A2|2013-10-16|

---

WO2012077119A3|2013-03-21|

---

US20160374351A1|2016-12-29|

---

CN103347529A|2013-10-09|

---

DK2648742T3|2019-07-15|

---

WO2012077119A2|2012-06-14|

---

CA2858505A1|2012-06-14|

---

BR112013014236A2|2020-06-09|

---

US9474283B2|2016-10-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2996540A|1956-07-30|1961-08-15|Sulphite Products Corp|Preparation of para-hydroxybenzoic acid|

---

JPS5520518B2|1976-04-14|1980-06-03|

---

JPS5622265B2|1977-04-07|1981-05-23|

---

US4511555A|1982-09-27|1985-04-16|Faust Valerie F|Herbal hair treatment compositions|

---

JPS6038317A|1983-08-12|1985-02-27|Kenichiro Uemura|Preparation of vegetable hair shampoo|

---

JP2588723B2|1987-09-09|1997-03-12|丸善製薬株式会社|Hair cosmetics|

---

HU202743B|1988-06-24|1991-04-29|Richter Gedeon Vegyeszet|Active ingredient composition comprising medicinal herb extracts, cosmetics comprising such active ingredient and process for producing medicinal and veterinary compositions|

---

CN1056525A|1990-05-11|1991-11-27|成都温江生物化工实用技术研究所|Oil is suffered from son, the neutral efficient detergent of Chinese honey locust|

---

JPH0657298A|1991-11-15|1994-03-01|Shiseido Co Ltd|Soap composition|

---

US5466675A|1992-02-04|1995-11-14|Piljac; Goran|Immunological activity of rhamnolipids|

---

US5455232A|1992-02-04|1995-10-03|Piljac; Goran|Pharmaceutical preparation based on rhamnolipid|

---

BE1005704A4|1992-02-04|1993-12-21|Piljac Goran & Piljac Visnja|Rhamnolipid based pharmaceutical preparation|

---

US5503766A|1993-04-06|1996-04-02|Natural Chemistry, Inc.|Enzymatic solutions containing saponins and stabilizers|

---

US5397778A|1994-02-25|1995-03-14|New England Deaconess Hospital Corporation|Enteral formulations for treatment of inflammation and infection|

---

FR2730634A1|1995-02-17|1996-08-23|Khayat Hanna|Cosmetic base contg. plant extracts e.g. ivy, mallow, elder and valerian|

---

KR0184779B1|1995-04-13|1999-04-01|성재갑|Saponine variants isolated and purified from quillaja saponaria|

---

RO110679B1|1995-04-27|1996-03-29|Sc Elixir Impex Srl|Antibacterial and against fungi action product preparation process|

---

US5639794A|1995-06-07|1997-06-17|Proguard, Inc.|Use of saponin in methods and compositions for pathogen control|

---

JP3453244B2|1996-03-13|2003-10-06|丸善製薬株式会社|Anti-yeast agent|

---

RU2124899C1|1997-02-10|1999-01-20|Алтайский государственный медицинский университет|Method of an antiulcer agent preparing|

---

JPH10298595A|1997-04-23|1998-11-10|Uerufuea:Kk|Natural soap containing bincho-zumi powder|

---

AU7174998A|1997-05-01|1998-11-24|Medlogic Global Corporation|Compositions for cosmetic applications|

---

EP1889623A3|1998-02-24|2009-04-08|Paradigm Biomedical Inc.|Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics|

---

CA2321926C|1998-02-24|2010-04-27|Tatjana Piljac|Use of rhamnolipids in a composition for the treatment of signs of aging|

---

US7262171B1|1998-02-24|2007-08-28|Paradigm Biomedical, Inc.|Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics|

---

RU2126687C1|1998-08-11|1999-02-27|Сибирский государственный медицинский университет|Agent showing holagogue effect|

---

JP2000191513A|1998-12-25|2000-07-11|Michio Yoshida|Skin washing agent containing agaricus mushroom extract solution|

---

EP1053782A1|1999-05-19|2000-11-22|Henry Chen|Method for manufacturing surfactant of natural plants|

---

JP2003500452A|1999-05-27|2003-01-07|アーマディーロ・ファーマシューティカルス・インコーポレーテッド|Pharmaceutical formulations of bioactive substances extracted from natural resources|

---

CN1085521C|1999-06-25|2002-05-29|张展洪|Sapindus mukorossi pulp shampoo and its preparing process|

---

EP1200100B1|1999-08-05|2010-07-14|Paradigm Biomedical Inc.|Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration|

---

RU2154480C1|1999-11-01|2000-08-20|Сибирский государственный медицинский университет|Method of treatment of patients with psoriasis in combination with chronic opisthorchiasis|

---

DE60111787T2|2000-01-31|2006-05-04|Shiseido Co. Ltd.|cleaning supplies|

---

RU2162701C1|2000-03-14|2001-02-10|ООО "Биолит"|Method of preparing agent with antiopisthorchiasis effect|

---

JP4589483B2|2000-05-12|2010-12-01|花王株式会社|Acne preventive and therapeutic agent|

---

JP3548093B2|2000-06-26|2004-07-28|象印マホービン株式会社|Rice cooker lid|

---

US6475476B1|2000-11-22|2002-11-05|Annette Fluker|Herbal hair treatments and method of making the same|

---

RU2179978C1|2000-11-24|2002-02-27|Воронежский государственный университет|Method of isolation of saponins|

---

CN1370515A|2001-02-14|2002-09-25|上海白猫有限公司|Shampoo made of natural plant material completely|

---

CN1344537A|2001-02-14|2002-04-17|上海白猫有限公司|Scurf-eliminating and itch-stopping shampoo of Chinese soapberry seed|

---

JP2002265327A|2001-03-13|2002-09-18|Chifure Keshohin:Kk|Cosmetic|

---

SE0101694D0|2001-05-14|2001-05-14|Swetree Genomics Ab|Novel sequences and their use|

---

JP2002363065A|2001-06-04|2002-12-18|Satoru Murakami|Herbal toilet soap and lotion|

---

AT413470B|2001-08-30|2006-03-15|Zorn Andrea|PROCESS FOR PREPARING A MEANS FOR PROPHYLAXIS AND / OR COMBATING AT LEAST ONE PLANT PEST|

---

JP2003096489A|2001-09-25|2003-04-03|Tsumura & Co|Solid soap|

---

CN1349792A|2001-11-06|2002-05-22|广东轻工职业技术学院|Composite shampoo with tea component and its making process|

---

JP2003267834A|2002-03-14|2003-09-25|Fancl Corp|Skin care preparation|

---

US6485711B1|2002-03-21|2002-11-26|Michael J. Olmstead|Organic toothpaste containing saponin|

---

US7001877B1|2002-04-01|2006-02-21|Grier Carol A|Organic laundry detergent and method of producing the same|

---

RU2210379C1|2002-05-13|2003-08-20|ООО "Биолит"|Antituberculosis agent|

---

BR0311170A|2002-05-22|2005-03-15|Unilever Nv|Method for providing a base topical composition for use in the preparation of a cosmetic topical composition, cosmetic composition, essentially anhydrous composition, use thereof, and parts kit for preparing a cosmetic composition|

---

JP2004331961A|2003-04-17|2004-11-25|Beauty Sapoo Kk|Soap|

---

RU2247571C2|2003-05-12|2005-03-10|ООО "Биолит"|Anti-inflammatory agent|

---

JP3678731B2|2003-05-28|2005-08-03|株式会社イトーキ|Stair classroom, lecture hall, training room and desk for listening|

---

RU2234913C1|2003-12-04|2004-08-27|Кочеров Максим Борисович|Agent "ginseng-2" for bath|

---

CA2460825A1|2004-03-10|2005-09-10|Sekar Balusamy|Eco-friendly biological consumer products |

---

SE0400996D0|2004-04-16|2004-04-16|Alltech Ireland Inc|Use of plants, plant extracts and nature-identical components from plants to affect rumen fermentation and to improve the energy and protein retention of ruminants|

---

US20060018867A1|2004-05-12|2006-01-26|Ichimaru Pharcos Co., Ltd|Cosmetic composition and production thereof|

---

JP2005343883A|2004-05-31|2005-12-15|Masamitsu Onishi|Acid-fast wasabi dentifrice, acid-fast bamboo grass tea, wasabi antibacterial soap, wasabi antibacterial shampoo, wasabi antibacterial therapeutic oil, acid-fast wasabi drink, acid-fast wasabi gum, and sailor wasabi pipe|

---

WO2006007741A1|2004-07-16|2006-01-26|Thoeny Rolf|Liquid detergent based on saponin|

---

ES2259933B1|2005-04-14|2007-11-01|Alfonso Iglesias Garcia|PROCEDURE FOR OBTAINING A RICH EXTRACT RICH IN SAPILLINAS DE KILLAY AND JABONCILLO COMBINED WITH ROMERO, SALVIA AND TOMILLO, EXTRACT OBTAINED AND ITS USE IN A MEDICINAL COMPOUND FOR THE TREATMENT OF VACCINES AND EQUIPMENT.|

---

RU2328301C2|2005-10-06|2008-07-10|Татьяна Владимировна Плесовских|Antibacterial, antiinflammatory ointment|

---

JP5622359B2|2006-02-10|2014-11-12|デユポン・テイト・アンド・ライル・バイオ・プロダクツ・カンパニー・エルエルシー|Bio-derived 1,3-propanediol and its conjugated esters as natural non-irritating solvents for biomass-derived extracts, fragrance concentrates, and oils|

---

JP4976706B2|2006-02-21|2012-07-18|北興化学工業株式会社|Method for producing palladium acetylacetonate|

---

KR100782599B1|2006-04-04|2007-12-06|바이오스펙트럼 주식회사|Naturotics|

---

EP2046930A4|2006-07-27|2012-06-27|Aurora Advance Beauty Labs|Rhamnolipid-based formulations|

---

JP5009594B2|2006-11-14|2012-08-22|学校法人関西大学|Antibacterial antifreeze protein-containing plant extract|

---

KR100821842B1|2006-11-30|2008-04-14|주식회사 엘지생활건강|Anti-allergy skin care cosmetic composition|

---

KR100821846B1|2006-11-30|2008-04-14|주식회사 엘지생활건강|Anti-dandruff hair care cosmetic composition|

---

WO2008079898A1|2006-12-20|2008-07-03|Pharmwest, Inc.|Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions|

---

JP2009007266A|2007-06-27|2009-01-15|Shin-Ei Chemical Co Ltd|Silver ion water for cosmetic and low-irritant cosmetic using the same|

---

FR2924123B1|2007-11-28|2009-12-04|Aux Jardins De La Saponine|DETERGENT PRODUCT BASED ON SAPINDUS FRUIT|

---

CN101214208A|2007-12-29|2008-07-09|丁杰|Ginsenoside liquid shampoo and its manufacturing method|

---

FR2927254B1|2008-02-12|2010-03-26|Lesaffre & Cie|USE OF NATURAL ACTIVE SUBSTANCES IN COSMETIC OR THERAPEUTIC COMPOSITIONS|

---

TWI340042B|2008-04-29|2011-04-11|Nat Univ Chiayi|Preparation of anti-dandruff bioactives from sapindus mukorossi and extended products containing the bioactives.|

---

US8217165B2|2008-06-17|2012-07-10|Pawan Kumar Goel|Process for the extraction of furostanolic saponins from fenugreek seeds|

---

CN100569214C|2008-11-06|2009-12-16|郴州邦尔泰苏仙油脂有限公司|Tea saponin shampoo and production technology|

---

WO2010077971A2|2008-12-17|2010-07-08|Harmony Laboratories, Inc.|Acne treatment powder foundation|

---

KR101087734B1|2008-12-29|2011-11-30|전라남도|Method for Purification of Saponin from Soapberry, Dichloro Methane Fraction of Soapberry, and Cosmetic Composition for Hair Comprising the Same|

---

CA2658873A1|2009-03-18|2010-09-18|Dirk Stass|Organic foaming agent and method of making same|

---

AU2010202421B2|2009-06-15|2014-05-08|Gojo Industries, Inc.|Method and compositions for use with gel dispensers|

---

US20110020302A1|2009-07-23|2011-01-27|Professional Compounding Centers Of America, Ltd.|Natural preservative blend|

---

CN102028640A|2009-09-24|2011-04-27|宋长碧|Low-stimulation and no-tear shampoo|

---

CN101732208B|2010-01-20|2011-07-20|云南省药物研究所|Application of Chinese medicinal composition in preparation of oil-controlling shampoo|

---

CN102247309A|2010-05-21|2011-11-23|吴苏|Shampoo with a mint tea fragrance, and preparation method thereof|

---

CN102379836A|2010-09-06|2012-03-21|赵斌|Pure natural plant children shampoo|

---

JP5616188B2|2010-10-04|2014-10-29|横浜油脂工業株式会社|Washing soap|

---

CN101978844A|2010-10-21|2011-02-23|蒋科罡|Health-care cold tea and preparation method thereof|

---

BR112013014236B1|2010-12-09|2021-03-30|Y&B Mother's Choice Ltd|COSMETIC OR CLEANING COMPOSITION AND CONSUMER PRODUCT|

---

US10064881B2|2010-12-09|2018-09-04|Y&B Mother's Choice Ltd.|Natural formulations|BR112013014236B1|2010-12-09|2021-03-30|Y&B Mother's Choice Ltd|COSMETIC OR CLEANING COMPOSITION AND CONSUMER PRODUCT|

---

US10434058B2|2010-12-09|2019-10-08|Y&B Mother's Choice Ltd.|Natural formulations|

---

US10064881B2|2010-12-09|2018-09-04|Y&B Mother's Choice Ltd.|Natural formulations|

---

JP5964172B2|2012-08-09|2016-08-03|花王株式会社|Method for suppressing adhesion of bacteria to hard surface|

---

JP6034118B2|2012-10-03|2016-11-30|一丸ファルコス株式会社|Deodorant, antibacterial agent, and skin external preparation composition containing them|

---

CN103767611B|2012-10-18|2017-02-01|云南白药清逸堂实业有限公司|Baby wet wipes for hip and production method thereof|

---

CN103110552B|2013-02-27|2016-06-22|新疆亲努尔生物科技有限公司|A kind of preparation method of salix caprea toothpaste|

---

US9217127B2|2013-08-05|2015-12-22|Greenology Products, Inc.|Organic cleaning composition|

---

US9217125B2|2013-08-05|2015-12-22|Greenology Products, Inc.|Organic cleaning composition|

---

US9447366B2|2013-08-05|2016-09-20|Greenology Products, Inc.|Organic cleaning composition|

---

IL229836D0|2013-12-08|2014-03-31|Y & B Mother S Choice Ltd|Preparations for suppressing or attenuating ocular irritancy|

---

WO2015148523A1|2014-03-24|2015-10-01|De Souza Louise|Soluble composition for treatment of hair and skin|

---

CZ306602B6|2014-12-04|2017-03-22|Agra Group A.S.|A preparation for protecting plants against insects|

---

CN104435333A|2014-12-09|2015-03-25|北京龙程菁华生物科技有限公司|Pepper total saponins and extracting method thereof|

---

CN104745316A|2015-02-10|2015-07-01|广东雅倩化妆品有限公司|Natural fruit and vegetable cleaning agent as well as preparation method and application of natural fruit and vegetable cleaning agent|

---

KR101799984B1|2015-06-01|2017-11-21|국민대학교산학협력단|Composition for Preveting Biofilm Formation Containing Extract of licorice|

---

CN104873440B|2015-06-11|2017-08-01|福建春辉生物工程有限公司|A kind of mildy wash containing saponin and preparation method thereof|

---

US10202497B2|2015-09-10|2019-02-12|Bridgestone Corporation|Microwave extraction technique for rubber and resin analysis|

---

CN105325467A|2015-10-31|2016-02-17|阜南县赵氏家庭农场|Pesticide for prevention and control of chili pests|

---

KR101978820B1|2016-02-02|2019-05-15|주식회사 휴앤코스메틱|Cleansing composition for skin or hair|

---

JP6956307B2|2016-05-02|2021-11-02|バイオ−アクティブス シナージオ リミテッドＢｉｏ−Ａｃｔｉｖｅｓ Ｓｙｎｅｒｇｉｏ Ｌｔｄ．|Composition of saponin and plant extract|

---

WO2017197396A1|2016-05-13|2017-11-16|Sanjeevita By Audubon, Llc|Saponin-containing compositions for use in textile wipes and related dispensers|

---

CN106010451B|2016-06-25|2018-10-23|陈玉兰|A kind of preparation method of the degradable dust suppressant of soft film type|

---

CN106178547A|2016-07-21|2016-12-07|鄢海军|A kind of bubble-water solution of the nontoxic non-stimulated health of child|

---

EP3534926A1|2016-11-02|2019-09-11|Alphanosos S.A.S.|Extract of an herbal composition as antimicrobial and/or antibiofilm agent|

---

CN106728251A|2016-12-05|2017-05-31|山东省科学院生物研究所|A kind of preparation method and application of bamboo willow antifungal activity component|

---

TWI642713B|2017-03-31|2018-12-01|臺灣塑膠工業股份有限公司|Superabsorbent polymer and the method of fabricating the same|

---

FR3064479B1|2017-03-31|2021-07-23|Jafer Entpr R&D S L U|COSMETIC COMPOSITIONS INCLUDING AN ASSOCIATION OF INGREDIENTS AND THEIR USES|

---

US10251832B2|2017-05-26|2019-04-09|Mary Kay Inc.|Cosmetic compositions and methods|

---

CN108977367A|2018-08-28|2018-12-11|中南林业科技大学|One plant of Aspergillus niger strain and its degradation cake of camellia oleifera seeds in Tea Saponin application|

---

CN109652247A|2018-11-27|2019-04-19|安徽省玉兔日用化学品有限公司|A kind of perfumed soap preparation process of the saponin(e containing natural plants|

---

EP3848019A1|2020-01-08|2021-07-14|CreaSearch BV|Cosmetic composion comprising a saponin and a probiotic component|

---

EP3848018A1|2020-01-08|2021-07-14|CreaSearch BV|Cosmetic composion comprising a saponin and a saccharide polymer|

---

US20210329913A1|2020-04-26|2021-10-28|Neozyme International, Inc.|Dry Powdered Compositions and Methods and Uses Thereof|

---

KR102318152B1|2020-08-21|2021-10-28|김교천|Elevated cover multi-function steam range to maintain uniform steam pressure|

---

CN112219864A|2020-10-30|2021-01-15|广东宇通医药生物科技有限公司|Chinese herbal medicine antibacterial liquid and preparation method thereof|

法律状态:
2020-06-23| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-06-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-09-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-11-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-01-19| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-03-30| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US42144010P| true| 2010-12-09|2010-12-09|

---

US61/421,440|2010-12-09|

---

PCT/IL2011/050053|WO2012077119A2|2010-12-09|2011-12-08|Formulations comprising saponins and uses thereof|

---